Cyclic nucleotide-gated (CNG) channels open in response to direct binding of cyclic nucleotide messengers. Every subunit in a tetrameric CNG channel contains a cytoplasmic ligand-binding domain (BD) that includes a β-roll (flanked by short helices) and a single C-terminal helix called the C-helix which was previously found to control efficacy (maximal open probability) and selectivity for cGMP vs.
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BD, stands out because of its extreme sensitivity to cAMP. Single-channel records ( Fig. 2A) show that 10 µM cAMP is sufficient to increase the open probability (P open ) of X-fA4 to >0.99 (only rare brief channel closures detected). X-fA4 is also sensitive to micromolar cGMP, but this property is not unique, appearing also in X-bA1, X-TAX4, and X-TAX2. However, these latter chimeras have K 1/2,cAMP more than an order of magnitude higher than K 1/2,cGMP . Thus the fCNGA4 BD in X-fA4 is unique in that its high sensitivity applies similarly to both agonists. {Table I and Fig. 2 here} A given subsaturating concentration of cGMP reliably elicited larger X-fA4 currents than did the same concentration of cAMP (Fig. 2B , upper traces). This cGMP selectivity was unexpected because the fCNGA4 BD has a methionine residue in its putative C-helix ligand contact position (11) , where other cGMP-selective X-chimeras (X-bA1, X-TAX4, and X-TAX-2) have aspartate. In fact, in the rCNGA4 BD, a methionine ligand-contact imparts cAMP selectivity(28,29), as confirmed in X-rA4 (12) . The cGMP selectivity of X-fA4 might thus suggest that the methionine in the fCNGA4 C-helix cannot form the ligand interaction required for cAMP selectivity, perhaps because of a different structure in this region. We disproved this possibility by constructing a new X-chimera, named X-rA4 R /fA4 C , which contains the roll subdomain of rCNGA4 (indicated by subscript R) and the C-helix of fCNGA4 (indicated by subscript C); this chimera shows cAMP selectivity at low agonist concentrations (Fig. 2B, C) . Fig. 2D summarizes K 1/2 measurements for cAMP and cGMP in individual patches of X-fA4, X-rA4, and XrA4 R /fA4 C , which all have the methionine ligand-contact. Even though the absolute K 1/2 values observed for a chimera varied from patch to patch, the K 1/2 selectivity of X-fA4 was always in favor of cGMP, whereas both X-rA4 and X-rA4 R /fA4 C always favored cAMP. This shows that the fCNGA4 C-helix has cAMP-selective determinants (presumably including the ligand-contact methionine) similar to those of the rCNGA4 C-helix. We propose that the intact fCNGA4 BD exhibits cGMP selectivity because the fCNGA4 roll subdomain contains some cGMP-selective elements, whose energetic contributions to gating properties outweigh those of the cAMP-selective C-helix. 
Efficacies compared using a new series of BD-substitution chimeras.
Comparisons of X-chimeras clearly show differences in BD sensitivity, but the K 1/2 parameter in isolation is poorly informative of microscopic physical processes such as ligand binding or channel opening(30). It is more valuable to compare the efficacy (maximal open probability, P max ) in saturating agonist concentrations where every channel should have uniform (i.e., maximal) BD occupancy.
Unfortunately, several X-chimeras have extremely high efficacy (e.g., X-fA4 in Fig. 2A ), and differences in their respective equilibrium constants for channel opening at saturating agonist concentration would not be easily detectable, because the numerical difference in their P max values would be too small. We predicted that BD-substitution chimeras using a design similar to the X-chimeras, but containing a different N-S2 sequence that disfavored intrinsic channel opening, might exhibit efficacies that were significantly less than unity; efficacy differences between chimeras would then be more readily apparent.
We therefore incorporated the BDs from modulatory subunits (rCNGA4, fCNGA4, TAX-2) into a new series of chimeras, called "RO-chimeras", in which the N-S2 sequence was that of intact bCNGA1 (see Fig. 3A ). The RO-chimeras still contain the P-loop of fCNGA2 to facilitate single-channel recording, but all sequence N-terminal of the P-loop matches exactly that of bCNGA1. All of the RO-chimeras were found to be capable of forming functional homomeric CNG channels, repeating our success with the Xchimeras. Table II summarizes the properties of the new RO-chimeras, and includes also RO-bA1 containing the bCNGA1 BD, which was called RO133 in previous studies (13, 21, (23) (24) (25) . Tables I and II) ; however, the absolute K 1/2 values are higher in the RO-chimeras than in corresponding X-chimeras, for any BD and any agonist. Besides this sensitivity difference, RO-chimeras have lower efficacy (Fig. 3A) than corresponding X-chimeras. RO-rA4, with the rCNGA4 BD, has mean P max,cAMP = 0.468 ± 0.090 (n = 3), whereas X-rA4 was previously (12) found to have a much higher P max,cAMP of 0.980 ± 0.025 (n = 5). RO-fA4, with the fCNGA4 BD, exhibits a high mean P max,cAMP of 0.974 by guest on http://www.jbc.org/ Downloaded from ± 0.034 (n = 5), but this efficacy is nonetheless lower than that of X-fA4, as evinced by far more frequent channel closures (compare Figs. 3A and 2A). Thus multiple observations show that introduction of the bCNGA1 N-S2 in RO-chimeras reliably reduced activation efficiency compared to the corresponding Xchimeras; nevertheless, each chimera retains the ability to form functional homomeric channels with particular agonist selectivity properties controlled by the BD sequence.
Even though RO-fA4 exhibits less efficient activation than X-fA4, its efficacy is nevertheless unusually high compared to other RO-chimeras. The mean P max,cAMP of RO-fA4 is more than double that of RO-rA4, and P max,cGMP for RO-fA4 (not measured directly) must be similar to P max,cAMP since I max,cAMP / I max,cGMP was essentially unity in macroscopic current experiments. Thus efficacy of RO-fA4 significantly surpasses that of RO-rA4, for both agonists (Fig. 3B) . Moreover, the cAMP efficacy of RO-fA4 far surpasses those of RO-chimeras with bCNGA1 and TAX-2 BDs, whose extremely low I max,cAMP / I max,cGMP values indicate low P max,cAMP . Thus, comparative analysis of the RO-chimera series confirms the previous analysis of the X-chimera series: the BD of the modulatory subunit fCNGA4 is unique in mediating extremely efficient activation by both cGMP and cAMP.
Identification of regions of the fCNGA4 BD responsible for high cAMP efficacy.
The unusually efficient cAMP activation of RO-fA4 must derive from residues in the fCNGA4 BD not conserved in the other BDs studied -but does this include the C-helix ligand-contact? To test the importance of this methionine residue in RO-fA4 we mutated it to aspartate; this should introduce the same mechanism for strong cGMP selectivity used in RO-bA1. This expectation is borne out in the mutated chimera, RO-fA4 Asp. Relative to RO-fA4, the aspartate mutation dramatically decreases the K 1/2 selectivity ratio more than 100-fold to (3.29 ± 0.42) × 10 -3 (n = 7), because K 1/2,cGMP is lower and K 1/2,cAMP is higher ( I max,cGMP from macroscopic experiments is higher than the ratio P max,cAMP / P max,cGMP from single-channel experiments, possibly because spontaneous "runup" drifts in activation properties (26) were more complete in macroscopic experiments.) Thus the strong cGMP selectivity of RO-fA4 Asp confirms our conclusion from X-rA4 R /fA4 C , that the predicted ligand-contact position of the fCNGA4 C-helix is indeed a selectivity determinant, just as it is in the other BDs studied.
{Fig. 4 here}
Although mutating the ligand-contact in RO-fA4 from methionine to aspartate did decrease cAMP efficacy, the cAMP efficacy of RO-fA4 Asp is still much higher than that of RO-bA1 which also has an aspartate ligand-contact ( Fig. 4A : compare RO-fA4 Asp, solid circles, with RO-bA1, solid triangles). Thus while the highly efficient cAMP activation mediated by the fCNGA4 BD is partly due to the presence of a cAMP-selective methionine ligand-contact, it is also due in significant part to residues distinct from the ligand-contact which are not conserved with the bCNGA1 BD. To locate residues responsible for the functional difference between RO-fA4 Asp and RO-bA1, we constructed a number of new RO-chimeras by substituting selected subsequences of the fCNGA4 BD one at a time into the bCNGA1 BD of RO-bA1. The C-helix ligand-contact was aspartate in every new chimera, and we used the resultant high cGMP efficacy to our advantage, estimating P max,cAMP rapidly from macroscopic current measurements of I max,cAMP / I max,cGMP . From P max,cAMP we calculated the Gibbs free energy of channel opening in saturating cAMP, ∆G sat,cAMP , with a negative value indicating favorable opening (see Experimental Procedures). The baseline reference for the "subregion replacement" chimeras is RO-bA1, with ∆G sat,cAMP = +9.4 ± 1.3 kJ/mol (n = 17); this value was subtracted from each chimera's ∆G sat,cAMP value to calculate ∆∆G sat , the net energetic effect of the sequence substitution.
The first five subregion chimeras, called RO-bA1{1} through RO-bA1{5}, together constitute a complete screen of the BD residues of RO-fA4 Asp (see Fig. 5A ). In each of these five chimeras, the bCNGA1 subsequence replaced contains many residues that are conserved between RO-bA1 and RO-fA4
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http://www.jbc.org/ Asp; the number of unconserved residues ranges from four to nine (Fig. 1C) . Fig. 5B and Table III shows that of these five chimeras, the highest cAMP efficacy (lowest ∆G sat,cAMP ) is found in RO-bA1{4}, with ∆∆G sat = -9.0 ± 1.9 kJ/mol (n = 12), a large (>3kT) energetic change in favor of opening. The subregion responsible for this phenotype starts at the beginning of the B-helix and ends five residues into the Chelix; this "hinge" structure bridges the junction between the two major subdomains of the BD. Within the hinge, might there be one amino acid difference that alone accounts for the difference between RObA1{4} and RO-bA1? For instance, a previous study(31) found that gating was affected by a mutation just before the conserved hinge proline, which is tyrosine 586 in bCNGA1 but phenylalanine in fCNGA4). We constructed two new chimeras, RO-bA1{4.1} and RO-bA1{4.2}, containing replacements of portions of the hinge, either N-or C-terminal to the dividing proline (see Fig. 5A ). Both of these exhibit enhanced cAMP efficacy relative to RO-bA1, with ∆∆G sat of about -5.0 kJ/mol (about 2kT). We conclude that the enhanced cAMP efficacy of RO-bA1{4} derives from multiple fCNGA4 residues in the hinge region, including one or more residues distinct from the previously studied position 586.
{Fig. 5 and Table III here} Replacing the hinge of RO-bA1 to make RO-bA1{4} did not reconstitute the extremely low ∆G sat,cAMP value of RO-fA4 Asp. We noticed that replacements of sequences N-terminal of the hinge region (the A-helix and β-roll) produced small but detectable enhancements of cAMP efficacy. We combined all the substitutions of RO-bA1{1}, {2}, and {3} in a new chimera, RO-bA1{1-3}, with a large ∆∆G sat = -8.6 ± 1.6 kJ/mol (n = 11), which is >3kT. This shows that fCNGA4 residues in different parts of the A-helix+β-roll sequence make a significant collective contribution (similar to that of the hinge) to the high efficacy of RO-fA4 Asp. We went further to test the effects of replacing the entire roll subdomain (A-helix, β-roll, and B-helix), a substitution analogous to those made previously in X-chimeras. The chimera RO-fA4 R /bA1 C , combining the substitutions from RO-bA1{1}, {2}, {3}, and {4.1}, has ∆G sat,cAMP lower than that of any of the initial subregion chimeras, and in fact slightly lower than that of RO-fA4 Asp itself. In complementary fashion we replaced the C-helix of RO-bA1 with that of RO-fA4 Asp to produce the chimera RO-bA1 R /fA4 C Asp, which combines the substitutions of RO-bA1{4.2} and {5}. This chimera has poor efficacy, similar to that of RO-bA1. Therefore the high cAMP efficacy of ROfA4 Asp can be largely explained by the roll subdomain residues found in fCNGA4 and not in bCNGA1.
It is notable that when several subregion replacements are combined in one chimera, a summation of their ∆∆G sat values approximates the ∆∆G sat for the resultant combination chimera. For instance, the ∆∆G sat values for swapping the two major BD subdomains separately (in RO-fA4 R /bA1 C and RObA1 R /fA4 C Asp) can be summed to make -12.2 ± 2.6 kJ/mol, which closely matches the effect of a complete BD swap (∆∆G sat = -11.9 ± 2.5 kJ/mol in RO-fA4 Asp,). Likewise, the sum of ∆∆G sat values for RO-bA1{1}, RO-bA1{2}, and RO-bA1{3} is -6.1 ± 3.7 kJ/mol, which is within kT of the ∆∆G sat value -8.6 ± 1.6 kJ/mol of RO-bA1{1-3}. Although summing multiple ∆∆G sat values introduces some imprecision in our assessment, it appears that several small subregions (mostly in the roll subdomain) make individually small contributions, which combine their energetic effects independently (i.e., additively) in the intact fCNGA4 BD to produce exceptionally high efficacy.
Distinct effects of BD subregions on cAMP and cGMP activation.
The favorable activity determinants identified in the fCNGA4 BD might in principle enhance cGMP activation as well as cAMP activation. Since RO-bA1 already has high cGMP efficacy(13,21) of P max,cGMP = 0.94 ± 0.03, any enhancement of cGMP activation from a fCNGA4 subregion replacement would be detectable as a decreased K 1/2,cGMP . agonist-independent manner, without discriminating between cAMP and cGMP. However, this cannot be correct, because as we argue below, selected chimeras provide exceptions to the general rule of correlated effects on cAMP and cGMP activation, and lead us to conclude that individual subregions control distinct structural features of the ligand-gating mechanism.
Some chimeras in our study have mutations in entirely different subregions but by coincidence have similar cAMP efficacy. For instance, fCNGA4 A-helix+β-roll replacement and fCNGA4 hinge replacement (in RO-bA1{1-3} and RO-bA1{4}, respectively) both produce similar ∆∆G sat values.
Strikingly however, RO-bA1{4} exhibits significantly weaker agonist sensitivity. Table III and Fig. 6A show that for either cGMP or cAMP, the K 1/2 for RO-bA1{4} (Fig. 6A , triangles) is 10-fold higher (P<10 -6 ) than that for RO-bA1{1-3} (circles). In fact, the K 1/2,cAMP of RO-bA1{4} (solid triangles) is even higher (P<0.02) than that of RO-bA1 (gray solid line). This means, for instance, that a 10 mM concentration of cAMP is not high enough to saturate the binding sites of RO-bA1{4}, as it would be for RO-bA1 or for RO-bA1{1-3}. Thus hinge replacement and A-helix+β-roll replacement both enhance the energetics of opening a channel that is fully liganded by cAMP, but hinge replacement additionally has a paradoxically deleterious effect on the channel's overall ability to bind cAMP. Hence these particular mutation sets in the hinge and A-helix+β-roll represent two different modifications to the ligand-gating energetics. While their effects on cAMP efficacy happen to be identical, their full mechanistic consequences (including those relevant to cGMP activation and cAMP binding) are in fact not identical.
{Fig. 6 here}
Comparison of RO-bA1{4} and RO-bA1 with another subregion chimera, RO-bA1{3}, further illustrates divergent mechanistic effects and moreover supports the notion that subregions outside the Chelix can govern agonist selectivity. The sequence replacement producing RO-bA1{3} starts with the PBloop and ends with the last (eighth) strand of the β-roll, so we call this sequence the "loop-β8" region. The cGMP dose-responses of RO-bA1{3} and RO-bA1{4} are nearly coincident ( governing cAMP activation and cGMP activation must differ at one or more steps, and it is at such a step that the loop-β8 region must interact with agonist to produce its cGMP-selective effect.
DISCUSSION
This study advances our understanding of structural features that control the energetics of the CNG channel mechanism and thereby tune the channel's overall response profile (sensitivity and efficacy for given agonists). First, we used the BD-substitution strategy for comparative analysis of highly divergent BD sequences, to identify a particular BD sequence which mediated unusually efficient channel activation and therefore deserved closer attention. Next, we showed that sizable energetic contributions to efficacy derived from sequences outside the previously studied C-helix ligand-contact, specifically the "hinge" sequence bridging the roll and C-helix subdomains, as well as the A-helix and β-roll sequences N-terminal of the hinge. Finally, we showed that multiple BD regions contributing to efficient function (such as the hinge or loop-β8) govern different features of the ligand-gating mechanism, since sequence changes in these regions affect efficacy, sensitivity, and selectivity in a differential manner.
BD-substitution chimeras enable systematic comparison of divergent BDs.
The success of our first study introducing BD-substitution chimeras(12) has been generalized here: functional homomeric CNG channels are formed by X-chimeras containing BDs of widely divergent subunits, including even TAX-2, a modulatory subunit in the B-subfamily. Moreover, both conventional and modulatory subunit BDs can accomodate the unfavorable channel opening energetics imparted by the bCNGA1 N-S2 region in RO-chimeras. BD-substitution chimeras thus represent a simple method (the only one available) for studying modulatory subunit BDs in the absence of conventional subunit BD sequence, and for making direct functional comparisons of a diverse pool of BD sequences.
The catfish CNGA4 BD produced extremely strong ligand sensitivity and high efficacy which were obviously exceptional among the six BDs surveyed, and its sequence may prove useful for engineering sensitive cyclic nucleotide biosensors for applications such as patch-cramming(32). Although the rat and fish CNGA4 orthologues both occur in olfactory epithelium, their BDs differ markedly in function, consistent with the numerous sequence differences that arose since the divergence of mammals from fishes (see Fig. 1B and C) . Notably, the catfish olfactory conventional subunit (fCNGA2) is by guest on November 4, 2016
http://www.jbc.org/ Downloaded from expected to coassemble with fCNGA4 in vivo, but has a BD whose function is inefficient compared to related mammalian BDs such as bCNGA1 (12) . We speculate that during evolution, gain-of-function mutations accumulated in the fCNGA4 BD as an adaptive compensation for deleterious mutations in the fCNGA2 BD. These mutations did not radically change the protein fold of the fCNGA4 BD, which retains the C-helix ligand-contact mechanism for agonist selectivity found in the bCNGA1 and rCNGA4
BDs. We believe that the fCNGA4 BD preserves the essential features of structure and mechanism typical of CNG channels, but fortuitously contains numerous particular amino acids favorable for activation.
Multiple subregions contribute to efficient BD function by distinct mechanisms.
We identified RO-fA4 Asp and RO-bA1 as a pair of chimeras with dramatically different function, and then sought elements responsible for this difference, which must lie within the BD region.
This could include not only BD tertiary structure differences but also differences in functionally important interactions between the BD and non-BD regions. We need not assume that every interaction between BD and non-BD regions will be replicated in every chimera; on the contrary, since the non-BD regions are invariant, a failure of one particular BD sequence to form such a required interaction would lead to the identification of the missing structural element of the BD as important for efficient activation.
Our systematic piecewise scan of the entire BD sequence is complementary to many previous studies of cyclic nucleotide-activated proteins which depended on homology models of the BD structure for the initial identificaton of particular residues with likely functional relevance. Several BD residues identified in this way were previously studied by mutagenesis (11, 22, 26, 31, (33) (34) (35) , but they are all either conserved between the two BDs examined here or else (bCNGA1 Tyr586) were shown here not to be sufficient to explain the observed functional differences. Another previous study (8) confirmation that the hinge is a prominent control element in CNG channels, without making assumptions about the (unknown) BD structure; yet we also establish that the energetic contributions of the A-helix+β-roll match those of the hinge region in magnitude.
We found that fCNGA4 sequences for different BD subregions influence efficacy without any marked synergistic effect, i.e., their energetic effects are additive, with no added advantage derived from being present in combination. Neither do the individual effects of distinct replacements occlude one another significantly, which would imply that both modified the same set of molecular interactions (36) .
Additivity also applies to the roll and C-helix subdomains, which have been envisioned (10, 35) as independently folded units separated by a flexible proline pivot. This contrasts with the previous finding(12) that synergistic subdomain interaction was a key factor enabling the rCNGA4 BD to produce higher efficacy than the fCNGA2 BD. The likely explanation is that some roll-C-helix interactions do contribute to efficacy, but these are all conserved in the fCNGA4/bCNGA1 BD pair and not conserved in the rCNGA4/fCNGA2 BD pair. The high efficacy of the fCNGA4 BD relative to the bCNGA1 BD does not depend on roll-C-helix interactions, but can be attributed to fCNGA4 roll subdomain residues working independently of the C-helix, i.e., directly contacting a part of the agonist that does not also contact the C-helix, or else interacting with non-BD residues.
Additivity of cAMP efficacy effects implies that subregions act independently, and the complete response profiles show further that the subregions participate in different control mechanisms. Thus, hinge replacement and A-helix+β-roll replacement have different effects on efficacy vs. binding.
Moreover, hinge replacement and loop-β8 replacement have different effects on cAMP vs. cGMP activation. This finding of agonist selectivity determinants distinct from the C-helix ligand contact reinforces earlier results in X-chimeras, showing that the fCNGA4 roll subdomain imparts K 1/2 selectivity for cGMP (Fig. 2) , and that the fCNGA2 roll subdomain causes cGMP-dependent desensitization (12) .
The existence of agonist-selective effects, and more generally the finding of distinct mechanisms of by open state stabilization in an agonist-independent manner, like the N-S2 region (21) . Thus models for CNG channel gating must identify plausible agonist-dependent mechanisms by which non-C-helix regions can contribute to efficient activation.
Proposed mechanisms.
Fig . 6C uses the BD of HCN2 (an ion channel from a family closely related to CNG channels (9)) to show putative locations of the BD subregions that we have identified as control elements. Various regions of the roll (including the loop-β8) are clearly implicated in binding the cyclic phosphate and ribose moieties of the ligand. However, formation of specific stable interactions between the ligand and its BD is by itself insufficient to promote channel opening. Rather, ligand-gating requires that interactions of the protein and agonist increase their stability during channel opening, so that more stable proteinagonist interactions form in the open channel than in the closed channel. In this regard, the hinge region is intriguing, because it lies at a remove from the binding pocket. An important contribution from the hinge is plausible in one mechanism proposed for CNG channels (35, 37) , which posits that docking of the Chelix ligand-contact is the key structural event stabilizing the open channel. In this "C-helix fit" model, the C-helix is a rigid but mobile element whose docking entails rearrangement of the hinge, so the stability of a particular hinge sequence in the open state vs. the closed state would be an efficacy determinant structurally independent of the ligand-contact. To rationalize the observation that the fCNGA4 hinge replacement simultaneously enhances cAMP efficacy and weakens cAMP binding, we speculate that in the closed channel, the fCNGA4 hinge structure is unusually unstable, yet places the Chelix in a position that blocks access of the ligand to the PB cassette. Thus the hinge region could control efficacy by an agonist-independent mechanism (consistent with a previous finding(31) for mutation of Tyr586 to alanine) but also indirectly affect the initial binding step in an agonist-dependent mechanism.
Unfortunately, the C-helix fit model does not readily explain the prominent effects of mutating the roll subdomain. On the contrary, in its minimal form this model implies a "functional polarity" in the BD, in which the β-roll controls only the initial binding of the agonist via the cyclic phosphate and ribose by guest on November 4, 2016
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Indeed, deformation of the PB cassette to fit the agonist molecule better is a defining feature of a model proposed for PKA and EPAC (8) . In this "PB fit" model, the PB cassette, B-helix, and C-helix form a network of bonds whose geometry rearranges during activation, so sequence differences in all these regions should determine the energetics of the activating transition. Another way to explain efficacy control by the β-roll is a "purine rotamer" concept, which was implicit in the original proposal of the Chelix fit model(11) but not explicitly stated: namely, that the cyclic nucleotide itself changes conformation during activation. The highly stable interaction between the purine ring and the C-helix in the open channel requires an anti conformation for the cyclic nucleotide (11, 38) ; the rotamer model simply posits that the cyclic nucleotide has a syn conformation in the closed channel that is stabilized (to a lesser extent) by one or more interactions between the purine ring and the β-roll, so that the activation transition requires rotation of the purine ring around its N-glycosidic bond. The β-roll itself need not change conformation, and the particular residues interacting with the purine might even be conserved in many CNG channels, but a small modification to roll geometry from introducing fCNGA4 sequence could destabilize its purine interaction, hence favoring purine rotation towards the C-helix and increasing efficacy.
The PB fit and the purine rotamer model both account for roll effects on efficacy and are not mutually exclusive, but the rotamer model has two notable advantages. First, it naturally separates mechanistic contributions of the C-helix ligand-contact, hinge, and β-roll regions, consistent with the finding that at least some sequence changes in these regions have independent effects on gating. Second, purine-roll interactions can explain easily how the β-roll can discriminate between cyclic nucleotides, as found in the loop-β8 replacement. For instance, in the HCN BD structure(9), the PB-loop interacts with the N2 atom of cGMP (absent from cAMP). It is not known whether that structure corresponds to an open or closed channel, and more importantly it remains to be seen whether roll residues interacting with the purine of either cAMP or cGMP can be identified in CNG channels. Synonym and reference for previous data X-fA4 catfish CNGA4 1.01 ± 0.17 (11) 0.73 ± 0.10 (11) 0.721 ± 0.034 (11) 0.991 ± 0.020 (11) X-rA4 rat CNGA4 81 ± 85 (9) 120 ± 140 (9) 1.45 ± 0.14 (9) 1.024 ± 0.019 (9) X-β (12) X-fA2 catfish CNGA2 643 ± 29 (6) 261 ± 12 (6) rat CNGA4 1800 ± 1300 (3) 5000 ± 1900 (3) 3.7 ± 1.6 (3) 2.10 ± 0.67 (3) RO-TAX2 C. elegans TAX-2 460 ± 190 (4) 13.5 ± 6.0 (5) 0.034 ± 0.019 (4) 0.167 ± 0.077 (5) RO-bA1 bovine CNGA1 2140 ± 410 (4) 55 ± 27 (18) 0.0196 ± 0.0088 (4) 0.025 ± 0.12 (17) RO-bA1{1-3} V487-C573 586 ± 63 (8) 1.48 ± 0.27 (9) 0.424 ± 0.098 (11) +0.8 ± 1.0 -8.6 ± 1.6 RO-bA1 R /fA4 C Asp D588-N613 n.d. 72 ± 25 (6) 0.0171 ± 0.0099 (7) +10.5 ± 1.7 +1.1 ± 2.1 RO-fA4 R /bA1 C V487-Y586 284 ± 71 (6) 0.361 ± 0.069 (6) 0.825 ± 0.054 (9) -4.0 ± 1.0 -13.3 ± 1.6
